EGFR and non-small cell lung carcinoma: In Chinese patients with advanced EGFR mutation‐positive NSCLC, median PFS was 13.1 months with erlotinib and 4.6 months with chemotherapy (HR, 0.16; 95%CI: 0.10, 0.26; p < 0.0001), which was 9.7 months and 5.2 months (HR, 0.37; 95%CI: 0.25, 0.54; p < 0.0001), respectively, in European patients.133, 134